These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 29125504)

  • 21. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of a Comparative Study on the Management of Scoliosis in Duchenne Muscular Dystrophy: Are Corticosteroids Decreasing the Rate of Scoliosis Surgery in the United States?
    Raudenbush BL; Thirukumaran CP; Li Y; Sanders JO; Rubery PT; Mesfin A
    Spine (Phila Pa 1976); 2016 Sep; 41(17):E1030-E1038. PubMed ID: 26926354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of β
    Kelley EF; Cross TJ; Snyder EM; McDonald CM; ; Hoffman EP; Bello L
    Respir Res; 2019 Oct; 20(1):221. PubMed ID: 31619245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy.
    van den Bergen JC; Schade van Westrum SM; Dekker L; van der Kooi AJ; de Visser M; Wokke BH; Straathof CS; Hulsker MA; Aartsma-Rus A; Verschuuren JJ; Ginjaar HB
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):92-8. PubMed ID: 23667215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
    Thayer S; Bell C; McDonald CM
    J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive database of Duchenne and Becker muscular dystrophy patients (0-18 years old) in East China.
    Li X; Zhao L; Zhou S; Hu C; Shi Y; Shi W; Li H; Liu F; Wu B; Wang Y
    Orphanet J Rare Dis; 2015 Jan; 10():5. PubMed ID: 25612904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45.
    Findlay AR; Wein N; Kaminoh Y; Taylor LE; Dunn DM; Mendell JR; King WM; Pestronk A; Florence JM; Mathews KD; Finkel RS; Swoboda KJ; Howard MT; Day JW; McDonald C; Nicolas A; Le Rumeur E; Weiss RB; Flanigan KM;
    Ann Neurol; 2015 Apr; 77(4):668-74. PubMed ID: 25612243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive genetic analysis of 961 unrelated Duchenne Muscular Dystrophy patients: Focus on diagnosis, prevention and therapeutic possibilities.
    Kumar SH; Athimoolam K; Suraj M; Das Christu Das MS; Muralidharan A; Jeyam D; Ashokan J; Karthikeyan P; Krishna R; Khanna-Gupta A; Bremadesam Raman L
    PLoS One; 2020; 15(6):e0232654. PubMed ID: 32559196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and Clinical Characteristics of a National Cohort of Paediatric Duchenne Muscular Dystrophy Patients in Norway.
    Annexstad EJ; Fagerheim T; Holm I; Rasmussen M
    J Neuromuscul Dis; 2019; 6(3):349-359. PubMed ID: 31381525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
    Bernert G; Hahn A; Köhler C; Meyer S; Schara U; Schlachter K; Trollmann R; Walter MC
    Nervenarzt; 2021 Apr; 92(4):359-366. PubMed ID: 33215271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink.
    Broomfield J; Abrams K; Latimer N; Guglieri M; Rutherford M; Crowther M
    Brain Behav; 2023 Dec; 13(12):e3331. PubMed ID: 37957895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of two corticosteroid regimens on brain volumetrics in patients with Duchenne muscular dystrophy.
    Geuens S; Van Dessel J; Govaarts R; Ikelaar NA; Meijer OC; Kan HE; Niks EH; Goemans N; Lemiere J; Doorenweerd N; De Waele L
    Ann Clin Transl Neurol; 2023 Dec; 10(12):2324-2333. PubMed ID: 37822297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data.
    Qian C; Klimchak AC; Szabo SM; Popoff E; Iannaccone ST; Gooch KL
    Adv Ther; 2024 Jun; 41(6):2519-2530. PubMed ID: 38698169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.